{"DataElement":{"publicId":"3009669","version":"1","preferredName":"Breast Carcinoma Proliferative Index Laboratory Procedure Performed Type","preferredDefinition":"A description of the breast carcinoma proliferative index type.","longName":"2979373v1.0:3009653v1.0","context":"NHLBI","contextVersion":"1","DataElementConcept":{"publicId":"2979373","version":"1","preferredName":"Breast Carcinoma Proliferative Index Laboratory Procedure Performed","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla._A measure of the number of cells in a tumor that are dividing (proliferating). May be used with the S-phase fraction to give a more complete understanding of how fast a tumor is growing._Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting._Executed and carried through to completion.","longName":"2979362v1.0:2241241v1.0","context":"NHLBI","contextVersion":"1","ObjectClass":{"publicId":"2979362","version":"1","preferredName":"Breast Carcinoma Proliferative Index Laboratory Procedure","preferredDefinition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit.  Breast carcinoma may affect both females and males.  It is the most common malignant tumor and the leading cause of carcinoma death in women.  Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation.  The widespread use of mammography has contributed in the detection of very early cancerous lesions (less than 2mm in diameter).  The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular).  Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route.  The most common site of lymph node involvment is the axilla.  Breast carcinomas infrequently occur in males (particularly elderly individuals and patients with Klinefelter's syndrome).  The therapy of breat carcinoma includes surgery, radiation therapy, hormonal therapy and chemotherapy, depending on the type and extend of the disease. --2002:A measure of the number of cells in a tumor that are dividing (proliferating). May be used with the S-phase fraction to give a more complete understanding of how fast a tumor is growing.:Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","longName":"C4872:C28042:C25294","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Breast Carcinoma","conceptCode":"C4872","definition":"A carcinoma arising from the breast, most commonly the terminal ductal-lobular unit. It is the most common malignant tumor in females. Risk factors include country of birth, family history, menstrual and reproductive history, fibrocystic disease and epithelial hyperplasia, exogenous estrogens, contraceptive agents, and ionizing radiation. The vast majority of breast carcinomas are adenocarcinomas (ductal or lobular). Breast carcinoma spreads by direct invasion, by the lymphatic route, and by the blood vessel route. The most common site of lymph node involvement is the axilla.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"No","displayOrder":"2"},{"longName":"Proliferative Index","conceptCode":"C28042","definition":"The percentage of cells in a biological specimen that are dividing.","evsSource":"RADLEX_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Laboratory Procedure","conceptCode":"C25294","definition":"Any procedure that involves testing or manipulating a sample of blood, urine, or other body substance in a laboratory setting.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C8053B0-00F0-03CC-E040-BB89AD4303D8","latestVersionIndicator":"Yes","beginDate":"2010-01-06","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-01-06","modifiedBy":"ONEDATA","dateModified":"2010-01-06","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2241241","version":"1","preferredName":"Performed","preferredDefinition":"Performed; carried out.","longName":"C38000","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Performed","conceptCode":"C38000","definition":"Executed and carried through to completion.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"F9FA7953-8839-043D-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-07-08","endDate":null,"createdBy":"SHIDED","dateCreated":"2005-07-08","modifiedBy":"ONEDATA","dateModified":"2005-07-08","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7C8053B0-016E-03CC-E040-BB89AD4303D8","latestVersionIndicator":"Yes","beginDate":"2010-01-06","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-01-06","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":".Updated def for \"breast carcinoma\".  No version needed. AK 9/19/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"3009653","version":"1","preferredName":"Proliferative Index Type","preferredDefinition":"A measure of the number of cells in a tumor that are dividing (proliferating). May be used with the S-phase fraction to give a more complete understanding of how fast a tumor is growing._Type; a subdivision of a particular kind of thing.","longName":"3009653v1.0","context":"NHLBI","contextVersion":"1","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"100","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Thymidine kinase","valueDescription":"Thymidine Kinase","ValueMeaning":{"publicId":"3009657","version":"1","preferredName":"Thymidine Kinase","longName":"3009657","preferredDefinition":"Human Thymidine Kinases (Thymidine Kinase Family) catalyze thymidine phosphorylation via ATP to deoxythymidine monophosphate. (NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Thymidine Kinase","conceptCode":"C17198","definition":"Human Thymidine Kinases (Thymidine Kinase Family) catalyze thymidine phosphorylation via ATP to deoxythymidine monophosphate. (NCI)","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F6AE9B9-950D-559F-E040-BB89AD437EAB","latestVersionIndicator":"Yes","beginDate":"2010-02-12","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"7F6AE9B9-9526-559F-E040-BB89AD437EAB","beginDate":"2010-02-12","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-12","modifiedBy":"ONEDATA","dateModified":"2010-02-12","deletedIndicator":"No"},{"value":"Proliferation associated","valueDescription":"Proliferation-Related Ki-67 Antigen","ValueMeaning":{"publicId":"3009658","version":"1","preferredName":"Proliferation-Related Ki-67 Antigen","longName":"3009658","preferredDefinition":"Antigen Identified by Monoclonal Antibody Ki-67, encoded by the MKI67 gene, is a nuclear antigen expressed in proliferating cells but not in quiescent cells, and required for maintaining cell proliferation. Expression of this antigen occurs preferentially during late G1, S, G2, and M phases of the cell cycle, while in cells in G0 phase the antigen cannot be detected. Consequently, the monoclonal antibody Ki-67 is used in tumor pathology to detect proliferating cells in neoplastic diseases. This antigen is located in the nucleus, predominantly localized in the G1 phase in the perinucleolar region. In the later phases it is also detected throughout the nuclear interior, being predominantly localized in the nuclear matrix. In mitosis, it is present on all chromosomes. This antigen contains 1 FHA domain. Two alternative splicing forms exist, Long and Short. (from Swiss-Prot) ","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Antigen KI-67","conceptCode":"C17675","definition":"Antigen KI-67 protein (3256 aa, ~359 kDa) is encoded by the human MKI67 gene. This protein is required for cell proliferation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F6AE9B9-9530-559F-E040-BB89AD437EAB","latestVersionIndicator":"Yes","beginDate":"2010-02-12","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-12","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"7F6AE9B9-9549-559F-E040-BB89AD437EAB","beginDate":"2010-02-12","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-12","modifiedBy":"ONEDATA","dateModified":"2010-02-12","deletedIndicator":"No"},{"value":"p21WAF1/CIP1","valueDescription":"Cyclin-Dependent Kinase Inhibitor 1","ValueMeaning":{"publicId":"3009660","version":"1","preferredName":"Cyclin-Dependent Kinase Inhibitor 1","longName":"3009660","preferredDefinition":"Cyclin-dependent kinase inhibitor 1 (164 aa, ~18 kDa) is encoded by the human CDKN1A gene. This protein is involved in cell cycle arrest.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclin-Dependent Kinase Inhibitor 1","conceptCode":"C17783","definition":"Cyclin-dependent kinase inhibitor 1 (164 aa, ~18 kDa) is encoded by the human CDKN1A gene. This protein is involved in cell cycle arrest.","evsSource":"RADLEX_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F6AE9B9-9556-559F-E040-BB89AD437EAB","latestVersionIndicator":"Yes","beginDate":"2010-02-12","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-12","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"7F6AE9B9-956F-559F-E040-BB89AD437EAB","beginDate":"2010-02-12","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-12","modifiedBy":"ONEDATA","dateModified":"2010-02-12","deletedIndicator":"No"},{"value":"Flow cytometry","valueDescription":"Flow Cytometry","ValueMeaning":{"publicId":"2974014","version":"1","preferredName":"Flow Cytometry","longName":"2974014","preferredDefinition":"A technique for counting, examining and sorting microscopic particles suspended in a stream of fluid.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Flow Cytometry","conceptCode":"C16585","definition":"A technique for counting, examining and sorting microscopic particles suspended in a stream of fluid.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7BCD2B56-10AD-3667-E040-BB89AD436539","latestVersionIndicator":"Yes","beginDate":"2009-12-28","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2009-12-28","modifiedBy":"KUMMEROA","dateModified":"2022-06-10","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"7F6AE9B9-9583-559F-E040-BB89AD437EAB","beginDate":"2010-02-12","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-12","modifiedBy":"ONEDATA","dateModified":"2010-02-12","deletedIndicator":"No"},{"value":"Cyclin E","valueDescription":"Cyclin E","ValueMeaning":{"publicId":"3009662","version":"1","preferredName":"Cyclin E","longName":"3009662","preferredDefinition":"A 50-kD protein that complexes with cdk2 in the late G1 phase of the cell cycle.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclin E","conceptCode":"C17490","definition":"A 50-kD protein that complexes with cdk2 in the late G1 phase of the cell cycle.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F6AE9B9-9590-559F-E040-BB89AD437EAB","latestVersionIndicator":"Yes","beginDate":"2010-02-12","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"7F6AE9B9-95A8-559F-E040-BB89AD437EAB","beginDate":"2010-02-12","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-12","modifiedBy":"ONEDATA","dateModified":"2010-02-12","deletedIndicator":"No"},{"value":"Cyclin D1","valueDescription":"G2/S-Specific Cyclin-D1","ValueMeaning":{"publicId":"3009664","version":"1","preferredName":"G2/S-Specific Cyclin-D1","longName":"3009664","preferredDefinition":"G1/S-specific cyclin-D1 (295 aa, ~34 kDa) is encoded by the human CCND1 gene. This protein is involved in the regulation of the G1/S transition of the cell cycle.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"G1/S-Specific Cyclin-D1","conceptCode":"C17988","definition":"G1/S-specific cyclin-D1 (295 aa, ~34 kDa) is encoded by the human CCND1 gene. This protein is involved in the regulation of the G1/S transition of the cell cycle.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F6AE9B9-95B5-559F-E040-BB89AD437EAB","latestVersionIndicator":"Yes","beginDate":"2010-02-12","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-12","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"7F6AE9B9-95CE-559F-E040-BB89AD437EAB","beginDate":"2010-02-12","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-12","modifiedBy":"ONEDATA","dateModified":"2010-02-12","deletedIndicator":"No"},{"value":"Cyclin-dependent kinase (CDK) inhibitors","valueDescription":"Cyclin-Dependent Kinase Inhibitor","ValueMeaning":{"publicId":"3009666","version":"1","preferredName":"Cyclin-Dependent Kinase Inhibitor","longName":"3009666","preferredDefinition":"A protein that plays a role in the inhibition of cyclin-dependent kinases.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Cyclin-Dependent Kinase Inhibitor Protein","conceptCode":"C18492","definition":"A protein that plays a role in the inhibition of cyclin-dependent kinases.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F6AE9B9-95DB-559F-E040-BB89AD437EAB","latestVersionIndicator":"Yes","beginDate":"2010-02-12","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"7F6AE9B9-95F4-559F-E040-BB89AD437EAB","beginDate":"2010-02-12","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-12","modifiedBy":"ONEDATA","dateModified":"2010-02-12","deletedIndicator":"No"},{"value":"3H-thymidine labeling index","valueDescription":"3H-Thymidine Labeling Index","ValueMeaning":{"publicId":"3009667","version":"1","preferredName":"3H-Thymidine Labeling Index","longName":"3009667","preferredDefinition":"A labeling index evaluating the percentage of cells present in the S-phase fraction.  It is used to determine the proliferative activity of tumor cells in a tissue sample.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"3H-Thymidine Labeling Index","conceptCode":"C85879","definition":"A labeling index evaluating the percentage of cells present in the S-phase fraction. It is used to determine the proliferative activity of tumor cells in a tissue sample.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F6AE9B9-9600-559F-E040-BB89AD437EAB","latestVersionIndicator":"Yes","beginDate":"2010-02-12","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-12","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"7F6AE9B9-9619-559F-E040-BB89AD437EAB","beginDate":"2010-02-12","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-12","modifiedBy":"ONEDATA","dateModified":"2010-02-12","deletedIndicator":"No"},{"value":"Topoisonmerase II alpha","valueDescription":"Topoisomerase II Alpha","ValueMeaning":{"publicId":"3009655","version":"1","preferredName":"Topoisomerase II Alpha","longName":"3009655","preferredDefinition":"Involved in chromosome condensation and segregation, topoisomerase II alpha is a homodimer that controls DNA topology by transient ATP-dependent double-strand breakage and rejoining.  Topoisomerase II alpha is also associated with the Pol II holoenzyme and required for chromatin-dependent co-activation and productive RNA synthesis.  (from OMIM 126430 and NCI)","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"DNA Topoisomerase 2-Alpha","conceptCode":"C17801","definition":"DNA topoisomerase 2-alpha (1531 aa, ~174 kDa) is encoded by the human TOP2A gene. This protein is involved in the modulation of DNA topology.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F6AE9B9-94E7-559F-E040-BB89AD437EAB","latestVersionIndicator":"Yes","beginDate":"2010-02-12","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-12","modifiedBy":"ONEDATA_WA","dateModified":"2023-02-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","id":"8796F3C7-D1F4-DF84-E040-BB89AD434560","beginDate":"2010-02-12","endDate":null,"createdBy":"MOROZOFA","dateCreated":"2010-05-27","modifiedBy":"ONEDATA","dateModified":"2010-05-27","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008557","version":"1","preferredName":"Lab Results","preferredDefinition":"the results of laboratory tests.","longName":"LAB_RESULTS","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B2CFBA7D-D009-7227-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-27","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-27","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"3009652","version":"1","preferredName":"Proliferative Index Type","preferredDefinition":"A measure of the number of cells in a tumor that are dividing (proliferating). May be used with the S-phase fraction to give a more complete understanding of how fast a tumor is growing.:Type; a subdivision of a particular kind of thing.","longName":"C28042:C25284","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Proliferative Index","conceptCode":"C28042","definition":"The percentage of cells in a biological specimen that are dividing.","evsSource":"RADLEX_CODE","primaryIndicator":"No","displayOrder":"1"},{"longName":"Type","conceptCode":"C25284","definition":"Something distinguishable as an identifiable class based on common qualities.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F6AE9B9-94BD-559F-E040-BB89AD437EAB","latestVersionIndicator":"Yes","beginDate":"2010-02-12","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-12","modifiedBy":"ONEDATA","dateModified":"2010-02-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F6AE9B9-94CE-559F-E040-BB89AD437EAB","latestVersionIndicator":"Yes","beginDate":"2010-02-12","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-12","modifiedBy":"KUMMEROA","dateModified":"2012-03-26","changeDescription":".","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2695319","version":"1","longName":"NMDP: CDEs to review","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"2964891","version":"1","longName":"2020r1: Breast Cancer Pre-HSCT Data","context":"NHLBI"}]},{"publicId":"3553940","version":"1","longName":"BRIDG","context":"NHLBI","ClassificationSchemeItems":[{"publicId":"4133055","version":"1","longName":"Version 3.2","context":"NHLBI"}]},{"publicId":"6685474","version":"1","longName":"Artificial Neural Network Algorithm for BRIDG Mapping","context":"NCIP","ClassificationSchemeItems":[{"publicId":"6685476","version":"1","longName":"Training Set","context":"NCIP"}]}],"AlternateNames":[{"name":"bc_base_diag_pro_index_sp","type":"NMDP_FN","context":"NHLBI"},{"name":"PerformedObservation:methodCode","type":"HCT_BRIDG","context":"NHLBI"}],"ReferenceDocuments":[{"name":"Specify the index used to rep","type":"Preferred Question Text","description":"Specify the index used to report the value:","url":null,"context":"NHLBI"},{"name":"BRIDG mapping path for CDE:3009669","type":"BRIDG Mapping Path","description":"PerformedObservationResult > PerformedObservation.methodCode WHERE PerformedObservation > DefinedObservation.nameCode = \"Determine Breast Carcinoma Proliferative Index\"","url":null,"context":"NHLBI"}],"origin":"NMDP:National Marrow Donor Program","workflowStatus":"RELEASED","registrationStatus":"Application","id":"7F6B17A1-5122-C3B0-E040-BB89AD437269","latestVersionIndicator":"Yes","beginDate":"2010-02-12","endDate":null,"createdBy":"LOHNESC","dateCreated":"2010-02-12","modifiedBy":"KUMMEROA","dateModified":"2021-08-18","changeDescription":".2021-8-18 ak System generated def displayed as alt def. Updated def for \"breast carcinoma\". No version needed. AK 9/19/12","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}